Amany Elbehary | Health and Medicine | Best Researcher Award

Posted on by New Scientists

Dr. Amany Elbehary | Health and Medicine | Best Researcher Award

Assistant lecturer at Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Egypt.

Dr. Amani Mohamed Ibrahim Mohamed is an accomplished Assistant Lecturer in the Department of Clinical Pathology at the Faculty of Medicine, Zagazig University. Born on January 26, 1986, Dr. Amani has established a reputable academic and clinical profile, contributing significantly to the fields of laboratory medicine and diagnostic sciences. She brings a rigorous approach to teaching and research, with a focus on advancing diagnostic accuracy and improving clinical outcomes through innovative laboratory practices. As a dedicated academic professional, Dr. Amani is committed to integrating teaching excellence with active research and community service. Her role at Zagazig University reflects her passion for fostering knowledge in medical laboratory sciences, particularly in clinical pathology. She is recognized among her peers for her meticulous work ethic, collaborative mindset, and dedication to student mentorship. With a robust educational foundation and a growing portfolio of research endeavors, Dr. Amani continues to contribute to the academic and healthcare sectors in Egypt. She maintains active communication with the scientific community through conferences, workshops, and academic collaborations. Her professional journey is driven by a profound interest in bridging the gap between laboratory diagnostics and clinical application, striving to enhance healthcare delivery and patient care through evidence-based medical laboratory practices.

Publication Profile

Google Scholar

Education

Dr. Amani Mohamed Ibrahim Mohamed pursued her academic career with a strong commitment to clinical and biomedical sciences. She obtained her Bachelor of Medicine and Surgery (M.B.B.Ch) from Zagazig University, one of Egypt’s leading medical schools. Following her undergraduate studies, she completed her Master’s degree in Clinical Pathology, also at Zagazig University, which laid the groundwork for her expertise in laboratory medicine. Her academic training emphasized diagnostic hematology, clinical chemistry, immunology, and molecular pathology, providing her with comprehensive knowledge of disease mechanisms and laboratory techniques. During her postgraduate studies, Dr. Amani actively participated in clinical laboratory rotations, case discussions, and academic seminars, which honed her diagnostic acumen and critical thinking abilities. She is currently pursuing her doctoral studies in Clinical Pathology, aiming to deepen her research competencies and clinical applications in hematopathology and laboratory-based diagnostics. Her educational journey has been marked by a continuous pursuit of academic excellence, scientific inquiry, and a passion for improving laboratory diagnostics. In addition to her formal education, Dr. Amani frequently engages in professional development through specialized courses and workshops in areas such as quality assurance, molecular diagnostics, and emerging diagnostic technologies, ensuring her skills remain aligned with modern medical and scientific standards.

Professional Experience

Dr. Amani Mohamed Ibrahim Mohamed serves as an Assistant Lecturer in the Department of Clinical Pathology at the Faculty of Medicine, Zagazig University. Since joining the department, she has played a vital role in academic instruction, laboratory supervision, and clinical teaching. Her responsibilities include delivering lectures and practical sessions to undergraduate and postgraduate students, contributing to curriculum development, and ensuring high standards in laboratory diagnostics. Dr. Amani collaborates closely with hospital laboratories affiliated with the university, where she supports diagnostic services in hematology, clinical chemistry, and immunopathology. She has also participated in multidisciplinary clinical meetings and contributed to case reviews, enhancing the integration of laboratory findings into clinical decision-making. Prior to her current academic role, she completed her residency and training in clinical laboratories, gaining hands-on experience in diagnostic testing, quality control, and patient-centered laboratory reporting. Her professional background combines both academic and clinical expertise, which enhances her ability to deliver practical, evidence-based education. Dr. Amani is also involved in supervising master’s and medical student research projects, guiding students through methodological design and data analysis. Her professional experience reflects a deep commitment to academic growth, clinical collaboration, and improving diagnostic education for the next generation of healthcare professionals.

Research Interest

Dr. Amani Mohamed Ibrahim Mohamed’s research interests lie at the intersection of clinical pathology, diagnostic innovation, and disease biomarker discovery. Her primary focus is on hematological malignancies, immunohematology, and molecular diagnostics. She is particularly interested in the identification and validation of novel biomarkers that can improve the early detection, diagnosis, and prognosis of various diseases, especially hematological cancers. Additionally, Dr. Amani explores the application of advanced diagnostic technologies, such as PCR-based techniques, flow cytometry, and automated hematology analyzers, in routine laboratory practice. Another area of her interest includes the study of inflammatory markers and their diagnostic relevance in autoimmune disorders and infectious diseases. She is also keen on investigating laboratory quality assurance and standardization procedures to enhance diagnostic accuracy and reliability. Her research often involves cross-disciplinary collaboration with clinicians, bioinformaticians, and molecular biologists, reflecting her integrative approach to laboratory medicine. As part of her academic role, she actively mentors students on research projects that align with her areas of interest. With a strong foundation in clinical pathology and a vision for diagnostic innovation, Dr. Amani aspires to contribute to translational research that bridges the gap between laboratory findings and clinical applications for improved patient care.

Research Skills

Dr. Amani Mohamed Ibrahim Mohamed has developed a comprehensive set of research skills that reflect her advanced training in clinical pathology and medical diagnostics. She is proficient in a wide range of laboratory techniques including blood smear examination, bone marrow aspirate evaluation, coagulation assays, immunoassays, and automated hematology analysis. Her molecular diagnostic skills encompass PCR, gel electrophoresis, and nucleic acid extraction techniques, which she has employed in various research settings. Additionally, she is skilled in ELISA, flow cytometry, and spectrophotometry, enabling her to carry out immunological and biochemical investigations with precision. Dr. Amani is adept at research design and methodology, statistical data analysis using SPSS and GraphPad Prism, and systematic literature reviews. She has received training in Good Clinical Laboratory Practices (GCLP), research ethics, and laboratory quality management systems. Furthermore, she is experienced in preparing research proposals, IRB submissions, and scientific presentations for academic conferences. Her ability to work both independently and collaboratively in research settings has allowed her to contribute meaningfully to several projects and academic discussions. Dr. Amani’s research skills are continually enhanced through workshops, courses, and hands-on laboratory supervision, all of which contribute to her ongoing development as a competent and innovative clinical researcher.

Awards and Honors

Throughout her academic and professional journey, Dr. Amani Mohamed Ibrahim Mohamed has received recognition for her dedication to clinical pathology and her contributions to medical education. She has been honored by the Faculty of Medicine at Zagazig University for her outstanding academic performance during both undergraduate and postgraduate studies. Her consistent excellence in coursework and laboratory practice earned her a place among the top students in her class, which paved the way for her recruitment as an academic staff member. In addition to her academic honors, she has received commendations from colleagues and supervisors for her commitment to teaching and mentorship. Dr. Amani has also been selected to participate in competitive training programs and workshops funded by the university and national health initiatives, reflecting her strong professional standing. Her poster and oral presentations at national medical conferences have received positive feedback and served to highlight her skills in scientific communication. Furthermore, she has been recognized for her active role in departmental activities, such as quality control audits and curriculum updates. These honors underscore Dr. Amani’s reputation as a diligent, knowledgeable, and forward-thinking medical professional, committed to advancing the standards of laboratory medicine and medical education in Egypt.

Author Metrics

Dr. Amani Mohamed Ibrahim Mohamed’s academic contributions have begun to gain recognition within the scientific and medical research communities. According to citation databases such as Google Scholar, her work has accumulated a total of 108 citations, reflecting the growing impact of her research in clinical pathology and related biomedical sciences. She has achieved an h-index of 6, which indicates that six of her published articles have each received at least six citations. This metric suggests a consistent level of scholarly influence across multiple publications. Furthermore, Dr. Amani holds an i10-index of 3, meaning that three of her articles have been cited ten times or more, underlining the quality and relevance of her most cited work. These metrics provide insight into her emerging academic visibility and research engagement. Her publications, primarily in the areas of hematology, immunopathology, and diagnostic biomarkers, contribute to advancing medical knowledge and laboratory practices. As she continues to expand her research activities and collaborate on interdisciplinary studies, her citation indices are expected to rise. Dr. Amani’s author metrics underscore her potential as a developing researcher and highlight the importance of her contributions to the field of clinical diagnostics and academic medicine.

Publications Top Notes

  • Impact of cytotoxin-associated gene A of Helicobacter pylori strains on microalbuminuria in type 2 diabetes
    Journal: Saudi Journal of Kidney Diseases and Transplantation
    Volume: 21(4)
    Citations: 35
    Year: 2010

  • MicroRNA‐199b expression level and coliform count in irritable bowel syndrome
    Journal: IUBMB Life
    Volume: 68(5)
    Citations: 14
    Year: 2016

  • Endoscopic band ligation of internal haemorrhoids versus stapled haemorrhoidopexy in patients with portal hypertension
    Journal: Arab Journal of Gastroenterology
    Volume: 12(1)
    Citations: 13
    Year: 2011

  • Annexin A2 versus AFP as an efficient diagnostic serum marker for hepatocellular carcinoma
    Journal: Journal of Gastroenterology and Hepatology Research
    Volume: 2(9)
    Citations: 8
    Year: 2013

  • Role of gallstones in typhoid carriage in Egyptian patients
    Journal: Journal of Microbiology and Infectious Diseases
    Volume: 2(4)
    Citations: 8
    Year: 2012

  • Current status of schistosomiasis in Egypt: parasitologic and endoscopic study in Sharqia Governorate
    Journal: Afro-Egyptian Journal of Infectious and Endemic Diseases
    Volume: 1(1)
    Citations: 8
    Year: 2011

  • Study of frequency of spontaneous bacterial empyema in cirrhotic patients with hepatic hydrothorax
    Journal: Journal of Gastroenterology and Hepatology Research
    Volume: 4(4)
    Citations: 6
    Year: 2015

  • Glutathione S‐Transferase M1 and T1 gene polymorphisms and the outcome of chronic hepatitis C virus infection in Egyptian patients
    Journal: Annals of Human Genetics
    Volume: 80(1)
    Citations: 5
    Year: 2016

  • Impact of oesophageal variceal injection on gastric varices in cirrhotic patients
    Journal: Journal of Gastroenterology and Hepatology Research
    Volume: 3(6)
    Citations: 4
    Year: 2014

  • Association of MnSOD Ala16Val genotype and activity with hepatocellular carcinoma risk in HCV-infected Egyptian patients
    Journal: Arab Journal of Gastroenterology
    Volume: 11(1)
    Citations: 4
    Year: 2010

Conclusion

Dr. Amani Mohamed Ibrahim Mohamed exemplifies the qualities of a dedicated academic and clinical pathologist with a passion for diagnostic excellence and medical education. Her professional journey reflects a solid foundation in medical sciences, strengthened by rigorous academic training and practical experience in clinical pathology. As an Assistant Lecturer at Zagazig University, she actively contributes to the academic development of students, the advancement of diagnostic practices, and the pursuit of impactful research. Her work in laboratory medicine combines traditional diagnostic techniques with emerging molecular approaches, demonstrating a commitment to innovation and quality. Dr. Amani’s research interests in hematology, immunopathology, and biomarker discovery position her as a promising contributor to the field of clinical diagnostics. Her technical expertise, research acumen, and teaching skills enable her to inspire the next generation of clinicians and researchers. Through continued professional development, participation in academic conferences, and interdisciplinary collaboration, she remains at the forefront of medical laboratory sciences in Egypt. Dr. Amani’s career embodies the integration of academic rigor, research innovation, and clinical service, marking her as a vital asset to both her institution and the wider healthcare community.

 

Xiaofeng Dai | Medicine Advances | Best Researcher Award

Posted on by New Scientists

Prof. Xiaofeng Dai | Medicine Advances | Best Researcher Award

Professor at The First Affiliated Hospital of Xi’an Jiaotong University, China.

Prof. Dr. Xiaofeng Dai is a distinguished expert in precision oncology and plasma medicine, currently serving as Professor and Research Theme Leader at the First Affiliated Hospital of Xi’an Jiaotong University. With dual PhDs in Systems Biology (Genetics) and Econo-Informatics from Finland, she integrates interdisciplinary knowledge across molecular oncology, bioinformatics, and translational medicine. Prof. Dai has established herself as a global leader in exploring the molecular and clinical applications of cold atmospheric plasma (CAP) therapy, publishing over 114 SCI-indexed articles with a cumulative impact factor of 806.74. She is the first or corresponding author of all these works, including four ESI highly cited papers. Her scientific achievements are further marked by 2 U.S. patents, 4 Chinese invention patents, and 10 software copyrights. She has secured and led national and industrial research funding exceeding 10 million RMB. Recognized for her pioneering work, Prof. Dai has received prestigious honors including Academician of the European Academy of Natural Sciences (2023), Outstanding Engineer Award (2022), and selection in the Jiangsu Province 333 High-level Talents Program (2024). As an active contributor to academic societies and a passionate educator, she is committed to translating advanced research into tangible clinical innovations.

Publication Profile

Scopus

Educational Details

  • Ph.D. in Econo-informatics, Aalto University, Finland (2016)

  • Ph.D. in Systems Biology – Genetics, Tampere University of Technology, Finland (2010)

  • M.Sc. in Bioinformatics, University of Tampere, Finland (2010)

  • M.Sc. in Molecular Biology, Chinese Academy of Agricultural Sciences, China (2006)

  • B.Sc. in Biotechnology, Central South University of Forestry and Technology, China (2003)

Professional Experience

  • 2023/06 – Present: Professor, Theme Leader – Precision Oncology, The First Affiliated Hospital of Xi’an Jiaotong University

  • 2017/06 – 2023/05: Professor, Theme Leader – Precision Medicine, Jiangnan University

  • 2014/02 – 2017/05: Associate Professor, Precision Medicine, Jiangnan University

  • 2016/12 – 2017/02: Visiting Scholar, Queensland University of Technology (QUT), Australia

  • 2013/10 – 2014/01: Principal Investigator, Chinese National Human Genome Center

  • 2011/02 – 2013/09: Senior Research Fellow, Helsinki University Central Hospital, Finland

  • 2010/02 – 2011/01: Senior Research Fellow, Institute for Molecular Medicine Finland

  • 2007/03 – 2011/01: Research Fellow, Tampere University of Technology, Finland

Research Interest

Prof. Dai’s research centers on cold atmospheric plasma (CAP)-based therapies in oncology and beyond. Her interests lie in exploring the molecular underpinnings of CAP’s selective cytotoxicity against malignant cells, investigating its influence on cancer stemness, metastasis, and tumor microenvironment. Expanding from cancer, her current work includes the use of CAP in immunomodulation, metabolic disorders, viral prevention, and vaccine enhancement. She also focuses on developing innovative CAP delivery systems such as ingestible CAP capsules and CAP-mediated photodynamic therapy, aiming to enhance its versatility and applicability. Prof. Dai is also addressing key translational barriers—such as CAP’s short-lived reactive components—by designing storage-stable and sustained-release solutions. Her research integrates bioinformatics, molecular biology, and plasma physics to decipher therapeutic pathways and identify CAP-mimicking biomolecules. Through computational modeling and synthetic chemistry, she is developing molecules with CAP-like efficacy, pushing forward the concept of molecular plasma medicine. Her goal is to create clinically adaptable, precision-targeted, and minimally invasive treatment solutions across a wide spectrum of diseases.

Research Skills

Prof. Dai is proficient in a broad array of interdisciplinary research techniques, spanning molecular biology, plasma physics, bioinformatics, and translational medicine. Her core expertise includes the design and execution of high-throughput omics experiments, real-time plasma-matter interaction studies, and in vitro/in vivo cancer models. She is skilled in CRISPR-based functional genomics, computational modeling of plasma-induced cellular responses, and RNA-seq data interpretation. Her strong background in systems biology enables her to construct multi-scale models that integrate molecular, cellular, and clinical data. She has extensive experience in developing biomedical devices and software tools tailored to plasma applications, backed by 10 software copyrights. Her ability to secure industrial partnerships and government funding demonstrates her leadership in translational research. Additionally, Prof. Dai has led cross-disciplinary teams to develop CAP-based interventions for autoimmune diseases, metabolic disorders, and infectious disease prevention. She is also adept at scientific communication, grant writing, project management, and mentoring junior researchers and students.

Awards and Honors

Prof. Dai’s research excellence and leadership have been widely recognized. In 2024, she was named a Level 3 recipient in the prestigious “333 High-Level Talent Program” of Jiangsu Province. In 2023, she was elected an Academician of the European Academy of Natural Sciences, highlighting her international stature. Her innovative research earned her the Outstanding Engineer Young Award in 2022 from the International Scientific Exchange Foundation of China. Earlier honors include being a member of the Dual Innovative Team of Jiangsu Province (2017), receiving the Six Talent Peaks Award (2016), and being named a Leading Talent for Social Undertakings in Wuxi (2015). These accolades underscore her sustained contributions to scientific innovation, particularly in the interdisciplinary domains of bioengineering, oncology, and plasma medicine. They also reflect recognition by both national and international academic bodies, industry collaborators, and government agencies. Her ability to integrate science, education, and clinical translation has made her a respected figure in China’s high-impact research ecosystem.

Author Metrics

  • Total Citations: 4,522

  • Citations by Documents: 4,063

  • Total Publications (Documents): 125

  • h-index: 29

Top Noted Publication

1. Advanced Science (2020)

Title: Innovative precision gene-editing tools in personalized cancer medicine
Journal: Advanced Science

  • IF (2023): ~17.5

  • JCR Rank: Q1 (Multidisciplinary Sciences)

  • Reason: Highly impactful, interdisciplinary, cutting-edge gene-editing research published in a top-tier journal.

2. Trends in Biotechnology (2018)

Title: The emerging role of gas plasma in oncotherapy
Journal: Trends in Biotechnology

  • IF (2023): ~20.0

  • JCR Rank: Q1 (Biotechnology & Applied Microbiology)

  • Reason: Published in a Cell Press journal, which is highly selective. Recognized for trend-setting reviews.

3. Signal Transduction and Targeted Therapy (2025)

Title: Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics
Journal: Signal Transduction and Targeted Therapy

  • IF (2023): ~39.3

  • JCR Rank: Q1 (Immunology/Oncology)

  • Reason: Nature Publishing Group journal with very high impact. Although recent, its publication in a Nature journal signifies top-tier status.

4. Trends in Genetics (2022)

Title: Histone lactylation: epigenetic mark of glycolytic switch
Journal: Trends in Genetics

  • IF (2023): ~12.0

  • JCR Rank: Q1 (Genetics & Heredity)

  • Reason: Cell Press review journal with major influence in the field of epigenetics and gene regulation.

5. Biotechnology Advances (2019)

Title: Standardizing CAR-T therapy: getting it scaled up
Journal: Biotechnology Advances

  • IF (2023): ~14.2

  • JCR Rank: Q1 (Biotechnology)

  • Reason: Authoritative journal in biotechnology with strong clinical and commercial relevance, especially in CAR-T research.

Conclusion

Prof. Dr. Xiaofeng Dai is a leading interdisciplinary scientist advancing cold atmospheric plasma (CAP) therapy in precision oncology and regenerative medicine. With dual Ph.D. degrees, over 100 SCI-indexed publications, and multiple patents, she bridges molecular research with clinical application. Her leadership in securing major research funding and fostering industry collaboration highlights her impact across science and innovation. As an educator and mentor, she is shaping future experts in cancer biology and bioinformatics. Through national and international partnerships, Prof. Dai remains at the forefront of translating high-impact research into real-world medical solutions.

 

Marwa Matboli | Molecular Biology | Women Researcher Award

Posted on by New Scientists

Prof. Dr. Marwa Matboli | Molecular Biology | Women Researcher Award

Marwa Matboli at Faculty of Medicine – Ain Shams University, Egypt.

Prof. Dr. Marwa Matboli is a distinguished Professor of Biochemistry and Molecular Biology at Ain Shams University, Egypt. With a robust academic and research background, she has significantly contributed to the fields of molecular diagnostics, bioinformatics, and translational medicine. Her work encompasses the exploration of non-coding RNAs in disease mechanisms, the application of computational tools in biomedical research, and the development of novel biomarkers for various diseases. She has held several key academic and administrative positions, demonstrating leadership in both educational and research domains.

Publication Profile

Scopus

Orcid

Google Scholar

Educational Details

  • MD in Medical Biochemistry and Molecular Biology, Ain Shams University, November 2012
    Thesis: Proteomic Analysis in Breast Screening Study
    Grade: GPA 3.12

  • MSc in Medical Biochemistry, Ain Shams University, May 2009
    Thesis: Detection of mRNA of Apoptosis Inhibition Gene in Urine of Bladder Cancer
    Grade: Excellent

  • M.B., B.Ch. in Medicine, Ain Shams University, December 2002
    Grade: Excellent 

  • Academic Visitor, St. George’s University of London, 2010–2012

Professional Experience

  • Professor, Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University (2023–Present)

  • Associate Professor, Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University (2018–2023)

  • Lecturer, Department of Medical Biochemistry, Ain Shams University (2013–2018)

  • Assistant Lecturer, Department of Medical Biochemistry, Ain Shams University (2009–2012)

  • Demonstrator, Department of Medical Biochemistry, Ain Shams University (2005–2009)

  • General Practitioner, Ain Shams University Hospitals (2002–2003); Ministry of Health (2003–2004)

  • Coordinator, Medical Biochemistry and Molecular Biology Department, Armed Forces College of Medicine (2016–2017)

  • Coordinator, Biomedical Research Department, Armed Forces College of Medicine (2016–2017)

  • Acting Head, Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Modern University for Technology and Information (July 2019–2023)

  • Director, Medical Research Unit, Faculty of Medicine, Modern University for Technology and Information (July 2019–September 2023)

  • Professor and Researcher, Molecular Biology Research Lab, Faculty of Oral & Dental Medicine, Misr International University

  • Coordinator, Genetic Module, Ain Shams Faculty of Medicine (2024–Present)

  • Coordinator, Courses in Genetic Engineering, Applied Genomic Technology, Genomics & Proteomics, and Computational Findings, Faculty of Artificial Intelligence, Delta University for Science and Technology (September 2024–Present)

Research Interest

Prof. Dr. Marwa Matboli’s research focuses on:

  • Non-coding RNAs (miRNAs, lncRNAs, circRNAs) in disease diagnostics and therapeutics

  • Bioinformatics and computational biology applications in medical research

  • Molecular mechanisms underlying metabolic disorders, including diabetes and non-alcoholic steatohepatitis

  • Cancer biomarker discovery and validation

  • Integration of machine learning models in biomedical data analysis

She has contributed to multiple international projects, including the development of the MicroRNA Childhood Cancer Catalog (M3Cs) Version 2.0 and the African Genomic Medicine Training Initiative (AGMT) course.

Author Metrics

  • Google Scholar

    • Total Citations: 2,057

    • h-index: 27

    • i10-index: 59

  • Scopus

    • Total Citations: ~1,550

    • h-index: 22

  • ResearchGate

    • Research Interest Score: 1,000.2

  • ORCID Id: 0000-0002-6852-3954

Top Noted Publication

1. Title: Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma
Authors: Kamel MM, Matboli M, Sallam M, Montasser IF, Saad AS, El-Tawdi AHF
Journal: Translational Research
Volume/Issue/Pages: 168, 134–145
Year: 2016
Impact Factor (2016): ~5.029
Category & Ranking (2016): Medicine, Research & Experimental (Q1)
Citations (Google Scholar): 148
Contribution: Co-author (Prof. Marwa Matboli)

2. Title: Urinary exosomal microRNA panel unravels novel biomarkers for diagnosis of type 2 diabetic kidney disease
Authors: Eissa S, Matboli M, Aboushahba R, Bekhet MM, Soliman Y
Journal: Journal of Diabetes and its Complications
Volume/Issue/Pages: 30(8), 1585–1592
Year: 2016
Impact Factor (2016): ~2.722
Category & Ranking (2016): Endocrinology & Metabolism (Q2)
Citations (Google Scholar): 132
Contribution: Co-author (Prof. Marwa Matboli)

3. Title: Clinical verification of a novel urinary microRNA panel: miR-133b, miR-342, and miR-30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis
Authors: Eissa S, Matboli M, Bekhet MM
Journal: Biomedicine & Pharmacotherapy
Volume/Pages: 83, 92–99
Year: 2016
Impact Factor (2016): ~2.759
Category & Ranking (2016): Pharmacology & Pharmacy (Q2)
Citations (Google Scholar): 119
Contribution: Co-author (Prof. Marwa Matboli)

4. Title: Caffeic acid attenuates diabetic kidney disease via modulation of autophagy in a high-fat diet/streptozotocin-induced diabetic rat
Authors: Matboli M, Eissa S, Ibrahim D, Hegazy MGA, Imam SS, Habib EK
Journal: Scientific Reports
Volume/Article: 7, Article number: 2263
Year: 2017
Impact Factor (2017): ~4.122
Category & Ranking (2017): Multidisciplinary Sciences (Q1)
Citations (Google Scholar): 94
Contribution: First author (Prof. Marwa Matboli)

5. Title: Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis
Authors: Eissa S, Matboli M, Essawy NOE, Kotb YM
Journal: Tumor Biology
Volume/Pages: 36, 9545–9552
Year: 2015
Impact Factor (2015): ~2.926
Category & Ranking (2015): Oncology (Q3) (Note: The journal was later retracted by the publisher in 2017 for multiple articles due to concerns about peer review integrity)
Citations (Google Scholar): 68
Contribution: Co-author (Prof. Marwa Matboli)

Conclusion

Prof. Dr. Marwa Matboli exemplifies the ideal candidate for the Women Researcher Award in Molecular Biology. Her exceptional scholarly output, academic leadership, and pioneering contributions to RNA biology, computational medicine, and translational diagnostics set her apart as a transformative figure in the biomedical field. By addressing minor visibility gaps at the global level, she can further elevate her profile as a leading international expert.

 

Chih-Pin Chuu | Prostate Cancer Research | Best Researcher Award

Posted on by New Scientists

Assoc. Prof. Dr. Chih-Pin Chuu | Prostate Cancer Research | Best Researcher Award

Associate Investigator at Institute of Cellular and System Medicine, National Health Research Institutes, Taiwan.

Dr. Chih-Pin Chuu is an Associate Investigator at the Institute of Cellular and System Medicine, National Health Research Institutes (NHRI), Taiwan, with joint appointments at several leading Taiwanese universities. He received his Ph.D. in Cancer Biology from the University of Chicago, and his B.S. in Physics with a minor in Life Sciences from National Tsing Hua University. His research focuses on the molecular mechanisms of prostate cancer progression and therapeutic resistance, with an emphasis on hormone therapy, cancer metabolism, and natural product-based treatment strategies. Dr. Chuu has published extensively in peer-reviewed journals and leads multiple interdisciplinary and translational projects funded by Taiwan’s NSTC. His contributions to cancer biology have been recognized with prestigious awards such as the National Innovation Award (2021) and NHRI Young Investigator Award (2017).

Publication Profile

Scopus

Google Scholar

Educational Details

  • Ph.D. in Cancer Biology, The University of Chicago, USA (2000–2005)

  • B.S. in Physics, National Tsing Hua University, Taiwan (1993–1997)

    • Minor: Life Sciences

Professional Experience

Dr. Chuu currently holds multiple academic and research positions:

  • Associate Investigator, Institute of Cellular and System Medicine, NHRI (2015–present)

  • Supervisor PI, Micro-Western Array Core Lab, NHRI (2010–present)

  • Adjunct Associate Professor, Graduate Institute of Clinical Medicine, Kaohsiung Medical University (2025–present)

  • Associate Professor (Joint Appointment), Department of Life Sciences, National Central University (2021–present)

  • Associate Investigator (Joint Appointment), National Defense Medical Center (2016–present)

  • Assistant/Associate Professor (Joint Appointment), China Medical University (2013–present)

  • Assistant/Associate Professor (Joint Appointment), National Chung Hsing University (2011–present)

Previous Roles Include:

  • Assistant Investigator, NHRI (2009–2015)

  • Postdoctoral Scholar, University of Chicago (2005–2009)

  • Acting Chief, Student Affairs Office, NHRI (2020–2022)

  • Academic Editor, PLOS ONE (2013–2021)

Research Interest

  • Prostate cancer biology, drug resistance in second-generation hormone therapies

  • Molecular oncology, cancer metabolism, tumor stemness and metastasis

  • Biomarker discovery, high-throughput proteomic profiling using Micro-Western Arrays

  • Natural products (e.g., green propolis, rooibos) in cancer prevention and treatment

  • Translational medicine, integrating clinical and proteogenomic data for diagnostics

Author Metrics

Name: Assoc. Prof. Dr. Chih-Pin Chuu

Top Noted Publication

1. Systems analysis of EGF receptor signaling dynamics with microwestern arrays

Authors: M.F. Ciaccio, J.P. Wagner, C.P. Chuu, D.A. Lauffenburger, R.B. Jones
Journal: Nature Methods, 7(2), 148–155
Year: 2010
Citation Count: 239
Summary: Introduced a novel high-throughput microwestern platform to analyze EGF receptor signaling dynamics; significant for systems biology and proteomic analysis.
Author role: Contributing author

2. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells

Authors: J. Fukuchi, J.M. Kokontis, R.A. Hiipakka, C. Chuu, S. Liao
Journal: Cancer Research, 64(21), 7686–7689
Year: 2004
Citation Count: 202
Summary: Demonstrated the ability of LXR agonists to inhibit proliferation in prostate cancer cells.
Author role: Co-author

3. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data

Authors: H.W. Cheng, Y.H. Liang, Y.L. Kuo, C.P. Chuu, C.Y. Lin, M.H. Lee, A.T.H. Wu, et al.
Journal: Cell Death & Disease, 6(5), e1753
Year: 2015
Citation Count: 167
Summary: Used bioinformatics and gene expression profiling to reposition thioridazine as an anticancer stem cell therapy.
Author role: Contributing author

4. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist

Authors: C. Chuu, R.A. Hiipakka, J.M. Kokontis, J. Fukuchi, R.Y. Chen, S. Liao
Journal: Cancer Research, 66(13), 6482–6486
Year: 2006
Citation Count: 151
Summary: Showed that LXR agonists combined with androgen inhibit tumor growth in vivo.
Author role: First author

5. Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks

Authors: C.P. Chuu, H.P. Lin, M.F. Ciaccio, J.M. Kokontis, R.J. Hause Jr, R.A. Hiipakka, et al.
Journal: Cancer Prevention Research, 5(5), 788–797
Year: 2012
Citation Count: 150
Summary: Explored anticancer mechanisms of CAPE in prostate cancer, linking it to mTOR and Akt pathway inhibition.
Author role: First author

6. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice

Authors: C. Chuu, R.A. Hiipakka, J. Fukuchi, J.M. Kokontis, S. Liao
Journal: Cancer Research, 65(6), 2082–2084
Year: 2005
Citation Count: 136
Summary: Reversal of castration resistance in prostate cancer by androgen reintroduction, proposing a paradoxical therapeutic approach.
Author role: First author

7. ASPM promotes prostate cancer stemness and progression by augmenting Wnt–Dvl-3–β-catenin signaling

Authors: V.C. Pai, C.C. Hsu, T.S. Chan, W.Y. Liao, C.P. Chuu, W.Y. Chen, C.R. Li, C.Y. Lin, et al.
Journal: Oncogene, 38(8), 1340–1353
Year: 2019
Citation Count: 135
Summary: Identified ASPM as a cancer stemness regulator via Wnt/β-catenin signaling in prostate cancer.
Author role: Co-author

8. Caffeic acid phenethyl ester is a potential therapeutic agent for oral cancer

Authors: Y.Y. Kuo, W.T. Jim, L.C. Su, C.J. Chung, C.Y. Lin, C. Huo, J.C. Tseng, S.H. Huang, C.P. Chuu, et al.
Journal: International Journal of Molecular Sciences, 16(5), 10748–10766
Year: 2015
Citation Count: 124
Summary: Showed CAPE’s effectiveness in oral squamous cell carcinoma via inhibition of proliferation and migration.
Author role: Co-author

9. Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines

Authors: C.P. Chuu, H.P. Lin
Journal: Anticancer Research, 30(9), 3643–3648
Year: 2010
Citation Count: 120
Summary: Demonstrated the broad antiproliferative activity of LXR agonists across various cancer types.
Author role: First author

10. Modulation of liver X receptor signaling as novel therapy for prostate cancer

Authors: C.P. Chuu, J.M. Kokontis, R.A. Hiipakka, S. Liao
Journal: Journal of Biomedical Science, 14, 543–553
Year: 2007
Citation Count: 118
Summary: A review highlighting LXR modulation as a potential therapeutic avenue in prostate cancer.
Author role: First author

Conclusion

Assoc. Prof. Dr. Chih-Pin Chuu stands out as a highly qualified and deserving candidate for the Best Researcher Award. His interdisciplinary research, particularly in the molecular mechanisms of cancer progression, therapeutic resistance, and natural compound-based interventions, has had a meaningful influence on cancer and cardiovascular-related biomedical science.

His record of scientific excellence, innovation, and sustained impact across academia and translational platforms make him a strong contender for this honor. With continued emphasis on global collaboration and clinical translation, his work is well-positioned to drive significant advancements in the field of oncology and beyond.